Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study

Toan T. Nguyen, Tanya L. Hoskin, Courtney N. Day, Elizabeth B Habermann, Matthew Philip Goetz, Judy C Boughey

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Adjuvant hormonal therapy (HT) reduces breast cancer recurrence risk in estrogen receptor-positive (ER+) ductal carcinoma in situ (DCIS). We assessed national practice patterns and influence of surgery and pathology on HT use in DCIS. Methods: Data on DCIS patients diagnosed from 2004 to 2014 were extracted from the National Cancer Database, and patients were classified according to ER status and whether HT was received. Factors associated with HT use were assessed using Chi square tests for univariate analysis and logistic regression for multivariate analysis. Results: Overall, 207,738 patients were evaluable as follows: ER+ (69.3%), ER− (13.7%), and ER unknown (17.0%). Among ER+ DCIS patients, 46.5% received HT, and HT use increased over time (42.3% in 2004 to 50.6% in 2014; p < 0.001). In contrast, 7.8% of ER− DCIS patients received HT, decreasing from 10.7% in 2004 to 5.9% in 2014 (p < 0.001). HT use varied by surgery type (BCS, 53.9%; unilateral mastectomy, 31.5%; and bilateral mastectomy, 8.1%; p < 0.001) and use was higher in BCS patients receiving adjuvant radiation than those not receiving radiation (62.7 vs. 29.1%; p < 0.001). Males treated with BCS were less likely to receive HT than females (43.2 vs. 54.0%; p < 0.001). In the BCS subset, higher use of HT was associated with more recent calendar year, age between 40 and 80 years, female sex, positive progesterone receptor status, and radiation use. Conclusion: Adjuvant HT use in ER+ DCIS has increased over time, with the highest rates in patients treated with BCS and radiation. While inappropriate HT use was observed in ER− and bilateral mastectomy patients, the frequency of use in these categories decreased over time.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalAnnals of Surgical Oncology
DOIs
StateAccepted/In press - Aug 1 2017

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Databases
Hormones
Neoplasms
Mastectomy
Therapeutics
Radiation
Progesterone Receptors
Chi-Square Distribution
Estrogen Receptors
Multivariate Analysis
Logistic Models
Regression Analysis

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ : A National Cancer Database Study. / Nguyen, Toan T.; Hoskin, Tanya L.; Day, Courtney N.; Habermann, Elizabeth B; Goetz, Matthew Philip; Boughey, Judy C.

In: Annals of Surgical Oncology, 01.08.2017, p. 1-10.

Research output: Contribution to journalArticle

@article{a49c000eaac84afeb83785b1af244973,
title = "Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study",
abstract = "Background: Adjuvant hormonal therapy (HT) reduces breast cancer recurrence risk in estrogen receptor-positive (ER+) ductal carcinoma in situ (DCIS). We assessed national practice patterns and influence of surgery and pathology on HT use in DCIS. Methods: Data on DCIS patients diagnosed from 2004 to 2014 were extracted from the National Cancer Database, and patients were classified according to ER status and whether HT was received. Factors associated with HT use were assessed using Chi square tests for univariate analysis and logistic regression for multivariate analysis. Results: Overall, 207,738 patients were evaluable as follows: ER+ (69.3{\%}), ER− (13.7{\%}), and ER unknown (17.0{\%}). Among ER+ DCIS patients, 46.5{\%} received HT, and HT use increased over time (42.3{\%} in 2004 to 50.6{\%} in 2014; p < 0.001). In contrast, 7.8{\%} of ER− DCIS patients received HT, decreasing from 10.7{\%} in 2004 to 5.9{\%} in 2014 (p < 0.001). HT use varied by surgery type (BCS, 53.9{\%}; unilateral mastectomy, 31.5{\%}; and bilateral mastectomy, 8.1{\%}; p < 0.001) and use was higher in BCS patients receiving adjuvant radiation than those not receiving radiation (62.7 vs. 29.1{\%}; p < 0.001). Males treated with BCS were less likely to receive HT than females (43.2 vs. 54.0{\%}; p < 0.001). In the BCS subset, higher use of HT was associated with more recent calendar year, age between 40 and 80 years, female sex, positive progesterone receptor status, and radiation use. Conclusion: Adjuvant HT use in ER+ DCIS has increased over time, with the highest rates in patients treated with BCS and radiation. While inappropriate HT use was observed in ER− and bilateral mastectomy patients, the frequency of use in these categories decreased over time.",
author = "Nguyen, {Toan T.} and Hoskin, {Tanya L.} and Day, {Courtney N.} and Habermann, {Elizabeth B} and Goetz, {Matthew Philip} and Boughey, {Judy C}",
year = "2017",
month = "8",
day = "1",
doi = "10.1245/s10434-017-5930-3",
language = "English (US)",
pages = "1--10",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",

}

TY - JOUR

T1 - Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ

T2 - A National Cancer Database Study

AU - Nguyen, Toan T.

AU - Hoskin, Tanya L.

AU - Day, Courtney N.

AU - Habermann, Elizabeth B

AU - Goetz, Matthew Philip

AU - Boughey, Judy C

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background: Adjuvant hormonal therapy (HT) reduces breast cancer recurrence risk in estrogen receptor-positive (ER+) ductal carcinoma in situ (DCIS). We assessed national practice patterns and influence of surgery and pathology on HT use in DCIS. Methods: Data on DCIS patients diagnosed from 2004 to 2014 were extracted from the National Cancer Database, and patients were classified according to ER status and whether HT was received. Factors associated with HT use were assessed using Chi square tests for univariate analysis and logistic regression for multivariate analysis. Results: Overall, 207,738 patients were evaluable as follows: ER+ (69.3%), ER− (13.7%), and ER unknown (17.0%). Among ER+ DCIS patients, 46.5% received HT, and HT use increased over time (42.3% in 2004 to 50.6% in 2014; p < 0.001). In contrast, 7.8% of ER− DCIS patients received HT, decreasing from 10.7% in 2004 to 5.9% in 2014 (p < 0.001). HT use varied by surgery type (BCS, 53.9%; unilateral mastectomy, 31.5%; and bilateral mastectomy, 8.1%; p < 0.001) and use was higher in BCS patients receiving adjuvant radiation than those not receiving radiation (62.7 vs. 29.1%; p < 0.001). Males treated with BCS were less likely to receive HT than females (43.2 vs. 54.0%; p < 0.001). In the BCS subset, higher use of HT was associated with more recent calendar year, age between 40 and 80 years, female sex, positive progesterone receptor status, and radiation use. Conclusion: Adjuvant HT use in ER+ DCIS has increased over time, with the highest rates in patients treated with BCS and radiation. While inappropriate HT use was observed in ER− and bilateral mastectomy patients, the frequency of use in these categories decreased over time.

AB - Background: Adjuvant hormonal therapy (HT) reduces breast cancer recurrence risk in estrogen receptor-positive (ER+) ductal carcinoma in situ (DCIS). We assessed national practice patterns and influence of surgery and pathology on HT use in DCIS. Methods: Data on DCIS patients diagnosed from 2004 to 2014 were extracted from the National Cancer Database, and patients were classified according to ER status and whether HT was received. Factors associated with HT use were assessed using Chi square tests for univariate analysis and logistic regression for multivariate analysis. Results: Overall, 207,738 patients were evaluable as follows: ER+ (69.3%), ER− (13.7%), and ER unknown (17.0%). Among ER+ DCIS patients, 46.5% received HT, and HT use increased over time (42.3% in 2004 to 50.6% in 2014; p < 0.001). In contrast, 7.8% of ER− DCIS patients received HT, decreasing from 10.7% in 2004 to 5.9% in 2014 (p < 0.001). HT use varied by surgery type (BCS, 53.9%; unilateral mastectomy, 31.5%; and bilateral mastectomy, 8.1%; p < 0.001) and use was higher in BCS patients receiving adjuvant radiation than those not receiving radiation (62.7 vs. 29.1%; p < 0.001). Males treated with BCS were less likely to receive HT than females (43.2 vs. 54.0%; p < 0.001). In the BCS subset, higher use of HT was associated with more recent calendar year, age between 40 and 80 years, female sex, positive progesterone receptor status, and radiation use. Conclusion: Adjuvant HT use in ER+ DCIS has increased over time, with the highest rates in patients treated with BCS and radiation. While inappropriate HT use was observed in ER− and bilateral mastectomy patients, the frequency of use in these categories decreased over time.

UR - http://www.scopus.com/inward/record.url?scp=85026500790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026500790&partnerID=8YFLogxK

U2 - 10.1245/s10434-017-5930-3

DO - 10.1245/s10434-017-5930-3

M3 - Article

C2 - 28766214

AN - SCOPUS:85026500790

SP - 1

EP - 10

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

ER -